Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-239-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-239-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-240-0002
lpv:speaker	lp:Thomas Ulmer2
lpv:spokenAs	unknown; Christlich Demokratische Union Deutschlands (2009-07-14--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 substitute; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 member; TRAN (2009-07-16--2012-01-18)3 vice-chair; Delegation for relations with Switzerland and Norway and to the EU-Iceland Joint Parliamentary Committee and the European Economic Area (EEA) Joint Parliamentary Committee (2009-09-17--2014-06-30)3
lpv:translated text	". I voted in favour of the report because it provides new bases for combating falsified medicinal products. There has been a gradual progression from, firstly, the sorts of medicinal products that are susceptible to falsification to later include other medicines in secure packaging. The marketing of medicinal products is prevented by the procedure of enquiry and readability. Increased protection is provided for consumers. The costs for the industry are manageable."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph